Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-Current Debt: 2017-2024

Historic Non-Current Debt for Ani Pharmaceuticals (ANIP) over the last 8 years, with Dec 2024 value amounting to $309.1 million.

  • Ani Pharmaceuticals' Non-Current Debt fell 4.87% to $297.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.7 million, marking a year-over-year decrease of 4.87%. This contributed to the annual value of $309.1 million for FY2024, which is 8.53% up from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Non-Current Debt is $309.1 million, which was up 8.53% from $284.8 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Non-Current Debt high stood at $309.1 million for FY2024, and its period low was $172.4 million during FY2020.
  • Over the past 3 years, Ani Pharmaceuticals' median Non-Current Debt value was $285.7 million (recorded in 2022), while the average stood at $293.2 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Non-Current Debt fell by 1.91% in 2020, and later surged by 66.15% in 2021.
  • Over the past 5 years, Ani Pharmaceuticals' Non-Current Debt (Yearly) stood at $172.4 million in 2020, then spiked by 66.15% to $286.5 million in 2021, then fell by 0.30% to $285.7 million in 2022, then declined by 0.30% to $284.8 million in 2023, then climbed by 8.53% to $309.1 million in 2024.